Lipidated interleukin-22 produced remarkable weight reductions of 20% as monotherapy and 40% when combined with GLP-1 receptor agonists in mice, while crucially preserving lean muscle mass with less than half the muscle loss seen with current treatments. The compound works through a distinct intestinal mechanism, increasing satiety hormone PYY secretion and doubling fecal energy loss by reducing calorie absorption in the gut. This represents a potentially transformative advance in obesity treatment. Current GLP-1 drugs like semaglutide and tirzepatide, while effective, often cause significant muscle loss alongside fat loss—a major clinical concern. The ability of lipidated IL-22 to maintain lean mass while achieving superior weight loss addresses this critical limitation. The additive effects suggest combination therapy could help the substantial portion of patients who don't reach target weights on GLP-1 drugs alone. However, translation from mouse models to humans remains uncertain, and the long-term safety profile of chronic IL-22 manipulation needs thorough evaluation. The gut-specific mechanism offers promise for targeted therapy with potentially fewer systemic side effects than current approaches.